The Europe atopic dermatitis drugs market size surpassed USD 5.07 billion in 2025 and is predicted to reach around USD 11.36 billion by 2035, registering a CAGR of 8.4% from 2026 to 2035.The market is growing due to awareness about skin health and strong access to innovative dermatology treatments.

Europe Atopic Dermatitis Drugs Market Statical Scope

In Europe the atopic dermatitis drugs market is driven by the increasing emphasis on patient-centered skin care and the expanding use of cutting-edge dermatology drugs. Demand for JAK inhibitors, biologics, and topical non-steroidal medications is rising in the area. The market is growing steadily thanks to supportive healthcare systems, continuing research partnerships, and growing awareness of long-term exzema management.

The market is growing due to rising demand for targeted eczema treatments, increased access to cutting-edge therapies, and increased knowledge of chronic skin conditions. The use of cutting-edge medications is being encouraged by supportive government healthcare systems and an increase in dermatology research activities. The Europe market is steadily expanding due to part to growing patient preferences for biologic therapies and personalized treatment approaches.

Europe Atopic Dermatitis Drugs Market Share, By Drug Class, 2025

• Corticosteroids - The corticosteroids segment dominated the Europe atopic dermatitis drugs market with a market share of 34% in 2025, driven by strong clinical adoption, affordability, and extensive use in managing inflammatory skin conditions. Favorable reimbursement policies and high treatment awareness are further supporting market demand across the region.
• Calcineurin Inhibitors -The calcineurin inhibitors segment represented a fast-growing segment in the Europe atopic dermatitis drugs market with a market share of 18% in 2025, driven by increasing preference for non-steroidal therapies and growing demand for long-term maintenance treatment. Rising dermatology consultations and expanding product availability are boosting segment growth.
• PDE4 Inhibitors - The PDE4 inhibitors segment held a notable share of 12% in the Europe atopic dermatitis drugs market in 2025, driven by growing demand for innovative targeted therapies and increasing adoption of advanced anti-inflammatory medications. Continuous research and product development activities are contributing to segment expansion

Europe Atopic Dermatitis Drugs Market Share, By Route of Administration, 2025

• Topical - The topical segment dominated the Europe atopic dermatitis drugs market by route of administration with a market share of 52% in 2025, driven by strong consumer preference for creams, lotions, and ointments due to their convenience and effectiveness. High availability of dermatology products across pharmacies further supports market growth.
• Parenteral - The parenteral segment accounted for a substantial market share of 28% in the Europe atopic dermatitis drugs market in 2025, driven by increasing utilization of biologics for severe atopic dermatitis treatment and rising investment in specialty dermatology care. Growing acceptance of injectable therapies among healthcare professionals is supporting demand.

Europe Atopic Dermatitis Drugs Market Share, By Distribution Channel, 2025

• Hospital Pharmacies - The hospital pharmacies segment held a significant market share of 38% in the Europe atopic dermatitis drugs market in 2025, driven by increasing use of advanced biologic therapies administered under specialist supervision and rising hospital-based dermatology treatments. Improved healthcare infrastructure and reimbursement support are contributing to segment growth.
• Retail Pharmacies -The retail pharmacies segment dominated the Europe atopic dermatitis drugs market by distribution channel with a market share of 47% in 2025, driven by widespread pharmacy networks, strong availability of dermatology medications, and increasing self-care treatment trends. Rising consumer access to prescription refill services is further accelerating market growth.

Competitive Analysis

In Europe, leading market participants are competing through innovative drug launches, research partnerships, and expansion of dermatology portfolios. Key companies including LEO Pharma, Novartis, Almirall, Sanofi, and Bayer AG are emphasizing advanced biologics and non-steroidal topical therapies to address rising patient demand for effective long-term treatment solutions. Strong regulatory support for novel therapies and growing investments in skin disease research are intensifying competition across the regional market.

Segments Covered in the Report

By Drug Class

• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

By Route of Administration

• Topical
• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies